CELYAD SA/ADR (CYAD) Receives “Buy” Rating from William Blair
A number of other equities research analysts also recently issued reports on CYAD. Zacks Investment Research downgraded shares of CELYAD SA/ADR from a hold rating to a sell rating in a research note on Monday, August 27th. Piper Jaffray Companies reduced their price objective on shares of CELYAD SA/ADR to $51.00 and set an overweight rating on the stock in a research note on Monday, November 12th. Finally, HC Wainwright reiterated a buy rating and set a $46.00 price objective on shares of CELYAD SA/ADR in a research note on Monday, November 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $44.20.
Shares of CELYAD SA/ADR stock opened at $21.30 on Tuesday. The stock has a market cap of $244.34 million, a price-to-earnings ratio of -6.02 and a beta of 1.35. CELYAD SA/ADR has a 12-month low of $20.54 and a 12-month high of $48.20.
CELYAD SA/ADR Company Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.